| Name | Title | Contact Details |
|---|
Since 1993 Letco Medical has been committed to providing compounding pharmacies complete customer satisfaction by offering the highest quality products, customer service, technical support and the fastest delivery times in the industry. Letco is your partner in compounding. We have an extensive line of chemicals, supplies, equipment, capsules, solutions and bases to support you. Letco Medical was also the first in our industry to offer CSOS ordering for your convenience. We also offer online ordering. We pride ourselves on knowing that satisfaction of a job well done is derived through a combination of hard work, perseverance and a thoughtful approach to do our best for our customers and our company. We communicate honestly and openly to continue to build long lasting, trustworthy relationships with our customers and employees. We thank you for trusting us as partners in your compounding pharmacy. We look forward to working with you.
Palvella Therapeutics was founded with the single-minded goal of serving individuals suffering from serious rare genetic diseases with no approved treatments.
Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Professor Sir David Lane, a recognized leader in the field of tumor suppressor biology, who discovered the p53 protein, founded the Company in 1996. In 1999, Cyclacel Pharmaceuticals was joined by Professor David Glover, a recognized leader in the mechanism of mitosis or cell division, who discovered, among other cell cycle targets, the mitotic kinases, Polo and Aurora, enzymes that act in the mitosis phase of the cell cycle. Sapacitabine (CYC682), Cyclacel`s most advanced product candidate, is the subject of SEAMLESS, a Phase 3 trial, which has completed enrollment and is being conducted under an SPA with the FDA as front-line treatment for acute myeloid leukemia (AML) in the elderly, and other indications including myelodysplastic syndromes (MDS). Cyclacel`s pipeline includes an oral regimen of seliciclib in combination with sapacitabine in a Phase 1 study of patients with Homologous Recombination (HR) repair-deficient breast, ovarian and pancreatic cancers, including BRCA positive tumors, and CYC065, a novel CDK2/9 inhibitor in a Phase 1 study of patients with solid tumors with potential utility in both hematological malignancies and solid tumors. Cyclacel`s strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a development pipeline of novel drug candidates. Cyclacel Pharmaceuticals` corporate headquarters are in Berkeley Heights, New Jersey, where our business development and medical and regulatory functions are also located. The company`s primary research facility is located in Dundee, Scotland. Dundee is the main location of our translational research and preclinical activities.
Diosynth is a Des Plaines, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Turn Biotechnologies develops mRNA medicines that induce the body to heal itself by instructing specific cells to fight disease or repair damaged tissue. We are focused on reprogramming the epigenome – a network of chemical compounds and proteins that control cell functions by influencing which genes are active – to restore capabilities that are often lost with age.